JPMorgan Chase & Co. Reaffirms “Underweight” Rating for GSK (LON:GSK)

GSK (LON:GSK)‘s stock had its “underweight” rating reiterated by stock analysts at JPMorgan Chase & Co. in a research report issued on Friday,Digital Look reports.

Separately, Berenberg Bank dropped their price objective on shares of GSK from GBX 1,820 ($23.56) to GBX 1,600 ($20.71) and set a “buy” rating for the company in a research report on Friday, November 29th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of GBX 1,805.83 ($23.38).

GSK Price Performance

Shares of GSK stock opened at GBX 1,483.50 ($19.21) on Friday. The business’s fifty day moving average price is GBX 1,453.58 and its 200 day moving average price is GBX 1,434.04. GSK has a twelve month low of GBX 1,282.50 ($16.60) and a twelve month high of GBX 1,823.50 ($23.61). The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64. The stock has a market capitalization of £60.20 billion, a P/E ratio of 23.96, a PEG ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK) last released its quarterly earnings data on Wednesday, February 5th. The company reported GBX 23.20 ($0.30) EPS for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. As a group, research analysts anticipate that GSK will post 175.980975 earnings per share for the current year.

Insider Activity

In other GSK news, insider Wendy Becker acquired 536 shares of the stock in a transaction on Thursday, March 20th. The stock was purchased at an average price of GBX 1,515 ($19.61) per share, for a total transaction of £8,120.40 ($10,513.21). Also, insider Emma Walmsley sold 120,653 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of GBX 1,453 ($18.81), for a total transaction of £1,753,088.09 ($2,269,663.50). Insiders own 1.61% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.